
Sheila K Patel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2694487/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nature Immunology, 2022, 23, 210-216.	14.5	486
2	Common Variants of the Novel Type 2 Diabetes Genes <i>CDKAL1</i> and <i>HHEX/IDE</i> Are Associated With Decreased Pancreatic Î ² -Cell Function. Diabetes, 2007, 56, 3101-3104.	0.6	226
3	Imbalance of the renin–angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target?. Gut, 2020, 69, 841-851.	12.1	160
4	Elevated plasma angiotensin converting enzyme 2 activity is an independent predictor of major adverse cardiac events in patients with obstructive coronary artery disease. PLoS ONE, 2018, 13, e0198144.	2.5	143
5	Angiotensin converting enzyme 2 activity and human atrial fibrillation: increased plasma angiotensin converting enzyme 2 activity is associated with atrial fibrillation and more advanced left atrial structural remodelling. Europace, 2017, 19, euw246.	1.7	138
6	Combination renin–angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions. Clinical Science, 2012, 123, 649-658.	4.3	116
7	From gene to proteinââ,¬â€experimental and clinical studies of ACE2 in blood pressure control and arterial hypertension. Frontiers in Physiology, 2014, 5, 227.	2.8	112
8	Plasma ACE2 activity is persistently elevated following SARS-CoV-2 infection: implications for COVID-19 pathogenesis and consequences. European Respiratory Journal, 2021, 57, 2003730.	6.7	100
9	Emerging markers in cardiovascular disease: Where does angiotensin onverting enzyme 2 fit in?. Clinical and Experimental Pharmacology and Physiology, 2013, 40, 551-559.	1.9	89
10	Plasma ACE2 Activity Predicts Mortality in Aortic Stenosis and Is Associated With Severe Myocardial Fibrosis. JACC: Cardiovascular Imaging, 2020, 13, 655-664.	5.3	88
11	The <i>ACE2</i> gene: its potential as a functional candidate for cardiovascular disease. Clinical Science, 2013, 124, 65-76.	4.3	83
12	Association of ACE2 Genetic Variants With Blood Pressure, Left Ventricular Mass, and Cardiac Function in Caucasians With Type 2 Diabetes. American Journal of Hypertension, 2012, 25, 216-222.	2.0	72
13	Low-Dose Levothyroxine Reduces Intrahepatic Lipid Content in Patients With Type 2 Diabetes Mellitus and NAFLD. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2698-2706.	3.6	70
14	Circulating high-molecular-weight RAGE ligands activate pathways implicated in the development of diabetic nephropathy. Kidney International, 2010, 78, 287-295.	5.2	69
15	Experimental and Human Evidence for Lipocalinâ€⊋ (Neutrophil Gelatinaseâ€Associated Lipocalin [NGAL]) in the Development of Cardiac Hypertrophy and Heart Failure. Journal of the American Heart Association, 2017, 6, .	3.7	59
16	Prevalence and predictors of cardiac hypertrophy and dysfunction in patients with TypeÂ2 diabetes. Clinical Science, 2008, 114, 313-320.	4.3	53
17	Chronic kidney disease: cardiac and renal angiotensin onverting enzyme (ACE) 2 expression in rats after subtotal nephrectomy and the effect of ACE inhibition. Experimental Physiology, 2012, 97, 477-485.	2.0	51
18	Variation in the ADIPOQ gene promoter is associated with carotid intima media thickness independent of plasma adiponectin levels in healthy subjects. European Heart Journal, 2008, 29, 386-393.	2.2	45

Sheila K Patel

#	Article	IF	CITATIONS
19	Influence of the ACE Gene Insertion/Deletion Polymorphism on Insulin Sensitivity and Impaired Glucose Tolerance in Healthy Subjects. Diabetes Care, 2008, 31, 789-794.	8.6	40
20	Usefulness of Retinal Microvascular Endothelial Dysfunction as a Predictor of Coronary Artery Disease. American Journal of Cardiology, 2015, 115, 609-613.	1.6	39
21	Advanced Glycation Urinary Protein-Bound Biomarkers and Severity of Diabetic Nephropathy in Man. American Journal of Nephrology, 2011, 34, 347-355.	3.1	38
22	Angiotensin converting enzyme 2 and diminazene. Current Opinion in Nephrology and Hypertension, 2016, 25, 384-395.	2.0	38
23	Short-Term Treatment with Diminazene Aceturate Ameliorates the Reduction in Kidney ACE2 Activity in Rats with Subtotal Nephrectomy. PLoS ONE, 2015, 10, e0118758.	2.5	36
24	Usefulness of the Charlson Co-Morbidity Index to Predict Outcomes in Patients >60 Years Old With Aortic Stenosis During 18 Years of Follow-Up. American Journal of Cardiology, 2012, 110, 695-701.	1.6	31
25	Retinal microvascular structure and function in patients with risk factors of atherosclerosis and coronary artery disease. Atherosclerosis, 2014, 233, 478-484.	0.8	31
26	Prevalence, predictors and evolution of echocardiographically defined cardiac abnormalities in adults with type 1 diabetes: an observational cohort study. Journal of Diabetes and Its Complications, 2014, 28, 22-28.	2.3	27
27	Impaired retinal microvascular function predicts long-term adverse events in patients with cardiovascular disease. Cardiovascular Research, 2021, 117, 1949-1957.	3.8	27
28	Diminazene Aceturate Improves Cardiac Fibrosis and Diastolic Dysfunction in Rats with Kidney Disease. PLoS ONE, 2016, 11, e0161760.	2.5	22
29	Progression of aortic stenosis in elderly patients over long-term follow up. International Journal of Cardiology, 2013, 167, 1226-1231.	1.7	21
30	The Receptor for Advanced Glycation End Products (RAGE) Is Associated with Persistent Atrial Fibrillation. PLoS ONE, 2016, 11, e0161715.	2.5	18
31	MicroRNAs mediate the cardioprotective effect of angiotensin-converting enzyme inhibition in acute kidney injury. American Journal of Physiology - Renal Physiology, 2015, 309, F943-F954.	2.7	17
32	Genetic Variation in Kruppel like Factor 15 Is Associated with Left Ventricular Hypertrophy in Patients with Type 2 Diabetes: Discovery and Replication Cohorts. EBioMedicine, 2017, 18, 171-178.	6.1	17
33	Age-dependent regulation of renal vasopressin V1A and V2 receptors in rats with genetic hypertension: implications for the treatment of hypertension. Journal of the American Society of Hypertension, 2013, 7, 3-13.	2.3	14
34	Plasma endothelin-1 and adrenomedullin are associated with coronary artery function and cardiovascular outcomes in humans. International Journal of Cardiology, 2019, 291, 168-172.	1.7	11
35	Adverse cardiac effects of exogenous angiotensin 1-7 in rats with subtotal nephrectomy are prevented by ACE inhibition. PLoS ONE, 2017, 12, e0171975.	2.5	11
36	Kruppel-Like Factor 15 Is Critical for the Development of Left Ventricular Hypertrophy. International Journal of Molecular Sciences, 2018, 19, 1303.	4.1	10

Sheila K Patel

#	Article	IF	CITATIONS
37	The CTGF gene â^'945 G/C polymorphism is not associated with cardiac or kidney complications in subjects with type 2 diabetes. Cardiovascular Diabetology, 2012, 11, 42.	6.8	7
38	Angiotensin-(1–7) and Kidney Disease: Friend or Foe. Hypertension, 2013, 62, e10.	2.7	3
39	Left ventricular hypertrophy in experimental chronic kidney disease is associated with reduced expression of cardiac Kruppel-like factor 15. BMC Nephrology, 2018, 19, 159.	1.8	3
40	Retinal microvascular function predicts chronic kidney disease in patients with cardiovascular risk factors. Atherosclerosis, 2022, 341, 63-70.	0.8	3
41	Development of Acute Decompensated Heart Failure Among Hospital Inpatients: Incidence, Causes and Outcomes. Heart Lung and Circulation, 2019, 28, 406-413.	0.4	2
42	Angiotensin onverting enzyme 2 polymorphisms and cardiovascular risk. Internal Medicine Journal, 2012, 42, 1167-1167.	0.8	1
43	Does left ventricular hypertrophy affect cognition and brain structural integrity in type 2 diabetes? Study design and rationale of the Diabetes and Dementia (D2) study. BMC Endocrine Disorders, 2017, 17, 24.	2.2	1
44	Angiotensin-Converting Enzyme 2 Activity Is Associated With Embolic Stroke of Undetermined Source. Stroke, 2021, 52, e324-e325.	2.0	0
45	Comment on Venskutonyte et al. Longitudinal Development of Left Ventricular Diastolic Dysfunction in Patients With Type 2 Diabetes. Diabetes Care 2014;37:3092–3097. Diabetes Care, 2015, 38, e62-e63.	8.6	0